Evaluating the Current and Future Opportunities for HIV PrEP

Clinician Moti Ramgopal, MD, FACP, FIDSA, highlights key components of a successful HIV PrEP program and comments on the role of providers in introducing these components throughout a patient’s continuum of care to maximize outcomes.

Considerations to help identify and increase utilization of PrEP therapy among patients who are eligible for treatment.

The financial burden associated with HIV and the potential effects of PrEP uptake on overall costs of care.

Payer perspective regarding strategies that can be deployed to help improve the patient/provider experience and utilization of PrEP therapy as prophylaxis against HIV.

Recommendations when talking with patients about goals of HIV PrEP and ensuring a patient-centered approach to care.

Discussion regarding HIV PrEP walkaway rates and strategies that can help support patients and increase adherence to therapy.

The advantages of coordinated care between multiple health care providers when managing patients on HIV PrEP therapy.

Strategies that can help address disparities in care for patients with HIV and reach high-risk groups of patients to ensure access to screening and PrEP.

Updates to the US Preventive Services Task Force grade A recommendation for HIV PrEP therapy and payer response to supporting providers and pharmacists who prescribe therapies used as prophylaxis.

An overview of HIV PrEP therapies in the pipeline and their potential roles as they are introduced into the community for use among high-risk populations.

Types of patients who will likely benefit from long-acting injectable PrEP therapies in the HIV treatment pipeline.

The benefits of addressing barriers and increasing access to HIV PrEP therapies to high-risk populations across the globe.

Carl Schmid discusses ideas on how to minimize barriers and increase overall use of PrEP therapy.

Carl Schmid describes the steps that can be taken to reduce inequities in PrEP uptake, focusing on community and provider education.

Carl Schmid explains the implications of PrEP therapies receiving a Grade A recommendation from the US Preventive Services Task Force.

Carl Schmid discusses the opportunities and challenges for use of long-acting PrEP therapy among available treatment options.

Carl Schmid concludes with his thoughts on the future of PrEP therapy.